Iacovelli Nicola Alessandro, Torrente Yvan, Ciuffreda Adriana, Guardamagna Vittorio A, Gentili Marta, Giacomelli Luca, Sacerdote Paola
Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Stem Cell Laboratory, Department of Pathophysiology and Transplantation, Universitá degli Studi di Milano, Milan, Italy.
Drugs Context. 2020 Jun 12;9. doi: 10.7573/dic.2020-4-7. eCollection 2020.
Approximately 95% of patients receiving radiotherapy (RT) will ultimately develop radiation-induced dermatitis (RID) during or after the course of treatment, with major consequences on quality of life and treatment outcomes. This paper reviews the pathophysiology of RID and currently used topical products for the prevention and treatment of RID. Although there is no consensus on the appropriate management, recent evidence suggests that the use of topical products supports to protect and promote tissue repair in patients with RID. Basic recommendations include advice to wear loose clothing, using electric razors if necessary, and avoiding cosmetic products, sun exposure or extreme temperatures. Based on mechanisms involved and on the clinical characteristics of oncological patients, the profile of the ideal topical product for addressing RID can be designed; it should have limited risk of adverse events, systemic adsorption and drug-drug interactions, should be characterized by multiple clinical activities, with a special focus on localized pain, and should have a careful formulation as some vehicles can block the RT beam.
接受放射治疗（RT）的患者中，约95%最终会在治疗期间或治疗后发生放射性皮炎（RID），这对生活质量和治疗结果有重大影响。本文综述了RID的病理生理学以及目前用于预防和治疗RID的局部用产品。尽管在适当的管理方面尚未达成共识，但最近的证据表明，使用局部用产品有助于保护和促进RID患者的组织修复。基本建议包括穿宽松衣物、必要时使用电动剃须刀、避免使用化妆品、暴露于阳光下或极端温度。根据所涉及的机制和肿瘤患者的临床特征，可以设计出用于解决RID的理想局部用产品的概况；它应具有有限的不良事件、全身吸收和药物相互作用风险，应具有多种临床活性，特别关注局部疼痛，并且由于某些载体可能会阻挡放疗束，因此应精心配制。
